Past studies have suggested tumor markers p53, p16, estrogen receptor, progesterone receptor and HER2/neu may have clinical utility in endometrial cancer for predicting lymph node metastasis, prognosis and in directing treatment [34]; however, no molecular markers are routinely used clinically. Here, PGR is linked to metastatic malignant neoplasm in the lymph nodes.